Dogs have rightfully earned the title of man’s best friend, not only for their companionship but also for the positive impact they have on their owners’ mental and physical well-being. Recent studies even suggest that having a canine companion can make you more attractive to potential partners.
Imagine a world where dogs could live forever, and this secret could unlock the key to longer, healthier lives for humans as well. Several companies are now working towards this common goal.
The Guardian view on ageing: the science of longevity is advancing | EditorialRead more
Loyal, a biotech start-up based in the US, is set to launch LOY-002, a beef-flavored pill that could potentially extend dogs’ healthy lifespan by at least one year. This innovative solution has attracted significant funding and attention from investors who see the potential benefits for both pets and humans.
Celine Halioua, the founder of Loyal, believes that understanding age-related decline in dogs can provide valuable insights into combating similar issues in humans. By targeting metabolic changes associated with ageing, their pill aims to improve overall health and vitality in aging pets.
In another part of America, researchers are exploring the use of rapamycin as a potential longevity drug for dogs. This drug has shown promising results in extending lifespan and addressing age-related disorders in mice.
The Dog Aging Project is conducting groundbreaking research on how low doses of rapamycin could enhance dogs’ heart and cognitive functions by regulating cell growth and metabolism. This study offers valuable insights that could pave the way for similar advancements in human longevity research.
Secrets of ageing: what makes me age? – podcastRead more
With ongoing efforts to understand aging processes better through canine studies, we may be one step closer to unlocking the secrets of extending both pet and human lifespans. The future looks bright with these innovative approaches towards promoting healthier aging for all species.
2024-12-26 13:00:47
Link from www.theguardian.com